Professor Mary Keogan:

A number of discussions are going on at European level. I am involved in the technical working group that looks at antigen tests. There are countries that have less access to PCR than we have or have other pressures. We do have the advantage of being an island where we can control travel a little bit more. We have the advantage of having more than adequate PCR capacity.

We are in a race between the variants and vaccination. As Professor Nolan alluded to earlier, we do not want to start importing cases when we have the option of using a better test.